Abstract
Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2.
All Keywords
【초록키워드】 SARS-CoV-2, Infectious diseases, technology, Infectious disease, Spike protein, Antibody therapeutics, Viral, vector, Vice President, vice, President, Regeneron Pharmaceuticals, the spike protein, Associate, 【제목키워드】 antibody, variant, therapeutic, age, SARS-CoV-2 spike,
【초록키워드】 SARS-CoV-2, Infectious diseases, technology, Infectious disease, Spike protein, Antibody therapeutics, Viral, vector, Vice President, vice, President, Regeneron Pharmaceuticals, the spike protein, Associate, 【제목키워드】 antibody, variant, therapeutic, age, SARS-CoV-2 spike,
{{{ 추상적인 }}}
Regeneron Pharmaceuticals의 연구, 전염병 및 바이러스 벡터 기술 담당 부사장인 Christos Kyratsous와 Regeneron Pharmaceuticals의 전염병 담당 부국장 Alina Baum이 SARS-CoV-2의 스파이크 단백질을 표적으로 하는 항체 치료제 개발에 대해 논의합니다.